Share

Company History


History Tracker

  • Foundation of CL Bencard a specialist allergy company in Devon, England.

  • Beecham Group Ltd acquires CL Bencard, a company specialising in allergy vaccines. It is a step forward towards ethical pharmaceutical products for the Beecham company.

  • Bencard Allergy moves from Brockham Park to Great West Road, London and opens the "Bencard Allergy Clinic"

  • Bencard acquires Wright-Fleming Institute, a small vaccine manufacturing business. Introduction of Influvac (influenza vaccine).

  • Launch of Pollinex vaccine containing grass pollen allergens in the UK.

  • Launch of Pollinex vaccine containing grass pollens in Germany.

  • Launch of Pollinex R (Ragweed) for the Canadian market.

  • Launch of Mugwort, Plantain, Parietaria and Olive in Pollinex for the Southern European markets.

  • Launch of Tyrosine S in Germany.

  • Launch of Pollinex containing tree allergens in Germany and general export markets.

  • Launch of Oralvac, a sublingual allergy desensitising vaccine in Germany.

  • Ribi Immunochem Research Ltd (now Corixa) sign an agreement with SmithKline Beecham for the use of the novel adjuvant MPL in the development of allergy vaccines.

  • MBI acquires Bencard business from SmithKline Beecham to form Allergy Therapeutics Ltd.

  • Launch of Pollinex Quattro in Germany. Allergy Therapeutics sets up new markets in Italy, Spain, Czech & Slovak Republics and Poland.

  • Allergy Therapeutics granted patent in USA for MPL/Tyrosine/Antigen.

  • Allergy Therapeutics signs license deal with PLIVA, the largest pharmaceutical company in Central & Eastern Europe.

  • Allergy Therapeutics appoints new Board of Directors.

  • Financial restructuring at Allergy Therapeutics.

  • Allergy Therapeutics and Novartis enter into an agreement to cooperate in the commercialisation of Novartis ophthalmology product Zaditen Optha.

  • Launch of Oralvac Plus.

  • Allergy Therapeutics floats on Alternative Investment Market, London.

  • Allergy Therapeutics commences dosing in Phase III POLLINEX Quattro Grass study.

  • Pivotal Phase III Pollinex Quattro Grass study meets primary efficacy endpoint

  • Pivotal Phase III Pollinex Quattro Ragweed study meets primary efficacy endpoint.

  • European patent granted for MPL-based sublingual vaccines.

  • Key technology patent for Pollinex Quattro granted in Japan.

  • New CEO appointed and Board strengthened.

  • Raised £24.4 million via a placing, subscription and offer and the exercise of warrants.

  • Ten further Market Authorisation Applications submitted in Germany.

  • FDA confirmed hold would be lifted on all three investigator drugs applications for Pollinex Quattro products.

  • Received the complete report from PEI on its Market Authorisation Application for Grass MATA MPL.

  • Graass MATA MPL dossier submitted in Switzerland.

  • Obtained exclusive distribution rights for UK and Ireland for epinephrine pen auto injector Anapen.

  • Allergy Therapeutics expands into Latin America in line with emerging market strategy.

  • Raised £13.3 million though a placing, subscription and offer and debt.

  • FDA clinical hold dated 2007 was lifted on grass pollen allergy vaccine.

  • Appointment of new R & D Director

  • US patent granted for a broad technology patent relating to Allergy Therapeutics’ family of MPL-based sublingual allergy vaccines.

  • Publication of paper:
    • A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy.
    • Aluminium in allergen-specific subcutaneous immunotherapy – a German perspective.
    • Probiotics in the Treatment of Chronic Rhinoconjunctivitis and Chronic Rhinosinusitis.

  • Health Canada approves submitted clinical trial application.







Share